Skip to main content
VERTEX PHARMACEUTICALS INC / MA logo

VERTEX PHARMACEUTICALS INC / MA — Investor Relations & Filings

Ticker · VRTX ISIN · US92532F1003 LEI · 54930015RAQRRZ5ZGJ91 US Manufacturing
Filings indexed 2,379 across all filing types
Latest filing 2025-01-17 Director's Dealing
Country US United States of America
Listing US VRTX

About VERTEX PHARMACEUTICALS INC / MA

https://www.vrtx.com/

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to discover, develop, and commercialize transformative medicines for serious diseases. The company is a leader in the field of cystic fibrosis (CF), having developed multiple therapies that treat the underlying cause of the disease for a significant portion of patients. Beyond its focus on CF, Vertex is advancing a research and development pipeline that includes potential treatments for other serious conditions such as sickle cell disease, beta-thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, and type 1 diabetes. The company's strategy is centered on a deep understanding of human biology to address the root cause of illness.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-01-17 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 20, 2024. It reports a regulatory event: FDA approval of a new drug (ALYFTREK) and the establishment of its wholesale acquisition cost. The document is short (3513 characters) and primarily serves as a regulatory disclosure of a material event rather than a detailed financial report or earnings release. It does not contain financial statements or detailed financial analysis. The content fits the profile of a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories. It is not an earnings release, capital update, or management report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-12-20 English
FORM 4
Director's Dealing
2024-11-19 English
Regulatory Filings 2024
Regulatory Filings
2024-11-15 English
FORM 4
Director's Dealing
2024-11-13 English
FORM 4
Director's Dealing
2024-11-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.